|
Asciminib Clinical Trials
5 actively recruiting trials across 2 locations
No change since May 2026
Also known as: ABL001
Pipeline
Phase 2: 4Phase 1/2: 1
Top Sponsors
- M.D. Anderson Cancer Center3
- Korean Society of Hematology1
- Gruppo Italiano Malattie EMatologiche dell'Adulto1
Indications
- Cancer5
- Chronic Myeloid Leukemia, Chronic Phase2
- Chronic Myeloid Leukemia2
- Chronic Myeloid Leukemia, BCR/ABL-Positive1
- Philadelphia Chromosome Positive1
Other2 trials
Houston, Texas2 trials
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
MD Anderson Cancer Center
Phase 2
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
The University of Texas MD Anderson Cancer Center
Phase 2
The Bronx, New York1 trial
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Montefiore Einstein Comprehensive Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.